JW Therapeutics was founded by Juno Therapeutics and WuXi AppTec Group in 2016.
By combining Juno's technology and platform with WuXi AppTec Group's local expertise, R and D and manufacturing platform, and broader partnerships, JW Therapeutics has successfully initiated the development of its first CD19-directed investigational therapy, JWCAR029 (a CAR-T therapy being studied for the treatment of B-cell malignancies initially focusing on relapsed and refractory DCBCL).
WuXi AppTec Group is a global pharmaceutical, medical device open-access capability and technology platform company with global operations.
The group provides a broad and integrated portfolio of services to help worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R and D through cost-effective and efficient solutions.
Juno Therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. Juno Therapeutics is a Celgene company.
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon
Enable Injections names new chief operating officer
BridgeBio Pharma and Kyowa Kirin partner on infigratinib for skeletal dysplasias in Japan
Redwood Scientific signs agreement with Jeeva Clinical Trials
Tissue Regenix ships first allograft products in the EU post-HPRA approval
Kromek secures GBP1.3m grant for AI-powered radiation sensor project